...
首页> 外文期刊>Seminars in Arthritis and Rheumatism >Long-term benefits and repeated treatment cycles of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee.
【24h】

Long-term benefits and repeated treatment cycles of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee.

机译:关节内透明质酸钠(Hyalgan)在膝关节骨关节炎患者中的长期获益和重复治疗周期。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To assess the long-term efficacy and tolerability of sodium hyaluronate (Hyalgan) after 1 cycle of 5 intra-articular (IA) injections in patients with osteoarthritis (OA) of the knee. The benefits of a second treatment cycle in patients with renewed need for therapy also were examined. METHODS: One hundred eight patients with knee pain (Kellgren-Lawrence grade 1, 2, or 3) for at least 20 days per month, and a score for pain on movement of at least 3.3 cm on a 10-cm Visual Analogue Scale (VAS) were treated with Hyalgan once weekly for 5 weeks in a multicenter, observational study. A repeat course was administered if patients continued to fulfill the inclusion criteria but not earlier than month 4. The primary efficacy parameter was pain on movement measured by VAS. Secondary parameters were pain on movement and pain at rest (5-point Likert ordinal rating scale), pain at rest (VAS), knee joint function (Larson scale), walking time, and global assessment of efficacy. RESULTS: The 59 patients completed the first 12-month follow-up period without the necessity for a second treatment cycle; 14 of the remaining 49 patients received a second treatment cycle. There were significant improvements in all efficacy parameters compared with the baseline values starting from 1 week after the last injection until month 12 for the 59 completed patients and also for all 108 enrolled patients (last observation carried forward). Safety and tolerability of Hyalgan were good or very good in more than 90% of patients. Of 4 patients who withdrew because of adverse events, only 1 event (knee joint effusion) was judged as possibly drug related. Two other adverse events judged to be drug related (generalized skin eruption; pruritus and knee joint effusion) resolved and did not lead to study withdrawal. CONCLUSION: The results of this observational study suggest that Hyalgan, administered either as a single or repeat course, is an effective and well-tolerated therapy for the long-term treatment of the pain of OA. Semin Arthritis Rheum 32:310-319.
机译:目的:评估透明质酸钠(Hyalgan)在膝关节骨关节炎(OA)患者中进行5次关节内(IA)注射1次周期后的长期疗效和耐受性。还检查了再次需要治疗的患者第二次治疗周期的益处。方法:108名膝关节疼痛患者(Kellgren-Lawrence 1、2或3级患者)每月至少有20天,并且在10厘米视觉模拟量表上的运动疼痛评分至少为3.3厘米(在多中心观察性研究中,每周一次用Hyalgan治疗VAS),持续5周。如果患者继续符合入组标准,但不早于第4个月,则应重复治疗。主要功效参数是通过VAS测量的运动疼痛。次要参数是运动时的疼痛和休息时的疼痛(5点Likert序数评分量表),休息时的疼痛(VAS),膝关节功能(拉森量表),步行时间以及整体疗效评估。结果:59例患者完成了前12个月的随访,无需第二个治疗周期。其余49位患者中有14位接受了第二个治疗周期。从最后一次注射后1周到第12个月,从基线值开始,所有功效参数均显着改善,这对59名已完成的患者以及所有108名已入组的患者(进行了最后观察)。在90%以上的患者中,Hyalgan的安全性和耐受性良好或非常好。因不良反应而退出的4名患者中,仅1例(膝关节积液)被判定可能与药物有关。被判定与药物相关的另外两个不良事件(皮肤普遍性发疹;瘙痒和膝关节积液)得以解决,并未导致研究退出。结论:这项观察性研究的结果表明,以单一疗程或重复疗程施用的Hyalgan是长期有效治疗OA疼痛的有效且耐受性良好的疗法。大黄精关节炎32:310-319。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号